Merck KGaA and SpringWorks Therapeutics, Inc. announced the companies have entered into a definitive agreement for Merck to acquire SpringWorks.

默克公司和SpringWorks Therapeutics宣布，双方已达成最终协议，默克将收购SpringWorks。

The purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) based on SpringWorks’ cash balance as of December 31, 2024, and a premium of 26% to SpringWorks’ unaffected 20-day volume-weighted average price of $37.38 on February 7, 2025, the day prior to the first market speculation of a potential transaction between Merck KGaA and SpringWorks.

每股 47 美元的现金收购价格代表了约 39 亿美元的股权价值，或基于 SpringWorks 截至 2024 年 12 月 31 日的现金余额计算的 34 亿美元（30 亿欧元）的企业价值，并且较 SpringWorks 在 2025 年 2 月 7 日（即默克公司与 SpringWorks 之间潜在交易首次市场传闻的前一天）未受影响的 20 日成交量加权平均价格 37.38 美元溢价 26%。

Upon closing, the business combination will immediately contribute to Merck’s revenues and is expected to be accretive to Merck’s earnings per share pre (EPS pre) in 2027. The acquisition will be funded with available cash and new debt. Beyond this planned transaction, Merck will retain the ability to pursue larger transactions and continue to evaluate opportunities across its three sectors, with Life Science a priority.

在交易完成时，这项业务合并将立即为默克公司带来收入，并有望在2027年对其每股收益（EPS pre）产生增值。此次收购将通过可用现金和新增债务来融资。除了这项计划中的交易，默克公司将继续保有追求更大规模交易的能力，并持续评估其三大领域的机遇，其中生命科学领域将是优先重点。

Merck is committed to preserving its strong investment grade credit rating. SpringWorks’ rare tumor portfolio, including a marketed first-in-class, systemic standard-of-care therapy for adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection, will accelerate immediate and sustainable revenue growth for Merck.

默克致力于保持其强劲的投资级信用评级。SpringWorks 的罕见肿瘤产品组合，包括已上市的首个用于治疗成人硬纤维瘤的一线系统性标准疗法，以及首个且唯一获批用于治疗无法完全切除的症状性丛状神经纤维瘤 (PN) 的成人和儿童神经纤维瘤病 1 型 (NF1) 患者的疗法，将为默克带来即时且可持续的收入增长。

SpringWorks’ portfolio complements Merck’s progress in rare tumors, with Merck recently exercising an option for worldwide commercialization rights for pimicotinib, an investigational therapy developed by Abbisko Therapeutics Co., Ltd. for patients with tenosynovial giant cell tumor (TGCT). The agreed acquisition provides SpringWorks with an opportunity to expand its reach into markets beyond the U.S.

SpringWorks的产品组合补充了默克在罕见肿瘤领域的进展，默克近期行使了对pimicotinib全球商业化权利的选择权。Pimicotinib是由上海益方生物科技有限公司开发的一种研究性疗法，针对腱鞘巨细胞瘤（TGCT）患者。此次约定的收购为SpringWorks提供了扩展到美国以外市场的机会。

and leverage the breadth of resources of Merck’s global Health.

利用默克全球健康资源的广度，

Type:

类型：

industry

工业